Crossject is revolutionizing needle free injection


Crossject is revolutionizing the administration of well-established treatments with its needle-free auto-injector ZENEO®. The prefilled, single-use device propels the medicine through the skin in less than a tenth of a second. Crossject currently has eight solutions in advanced stages of development, seven of which are for emergency situations.  

Zeneo illustration


Our news

Image de l'actualité

Confluence Innovation Bio Health Summit

Résumé de l'actualité

 May 10-14, 21

Image de l'actualité

ZENEO® Awarded

Résumé de l'actualité

by the Human Factors and Ergonomics Society (HFES)


Financial news: US & Canada licensing agreement with Eton Pharmaceuticals for Crossject’s ZENEO® Hydrocortisone

Sommaire ou résumé

Patrick Alexandre, CEO of Crossject, said: ‘‘We are proud to announce a sound commercial agreement for ZENEO® Hydrocortisone in the US and Canada with an American leader in Adrenal Insufficiency. Eton has successfully established strong relations with the patient communities and medical specialists that are its core focus. ZENEO® Hydrocortisone answers a medical need.